INDV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Indivior Pharmaceuticals, Inc (INDV) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong financial growth, positive analyst sentiment, and a share repurchase program that supports long-term value. Despite neutral technical indicators and no recent proprietary trading signals, the stock's fundamentals and positive catalysts outweigh short-term technical concerns.
The technical indicators are neutral. The MACD histogram is negative but contracting, RSI is at 47.353 (neutral zone), and moving averages are converging. The stock is trading near its pivot point (33.954), with resistance at 35.172 and support at 32.735. Short-term stock trend analysis suggests a slight decline in the next week and month.
Q4 2025 earnings exceeded expectations with a 20.1% YoY revenue increase and non-GAAP EPS of $0.
Announced a $400 million share repurchase program, signaling confidence in the company's valuation.
Analysts have raised price targets significantly, with Northland increasing to $50 and Morgan Stanley to $36, both maintaining positive ratings.
Gross margin dropped by 6.28% YoY in Q3 2025, which could indicate cost pressures.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
Short-term stock trend analysis predicts minor declines in the next week and month.
Indivior's Q4 2025 revenue increased by 4% YoY to $1.24 billion, and non-GAAP EPS was $0.82. In Q3 2025, revenue grew by 2.28% YoY, net income surged by 90.91% YoY, and EPS increased by 94.12% YoY. However, gross margin declined to 73.57, down 6.28% YoY.
Analysts are bullish on INDV. Northland raised its price target to $50, citing a valuation disconnect and strong fundamentals. Morgan Stanley raised its target to $36, highlighting low valuation premiums and intact fundamentals in the EU Pharmaceuticals sector.
